8-K: Arcadia Biosciences Reports Q4, Full-Year 2025 Results

Arcadia Biosciences announced its fourth-quarter and full-year 2025 financial results, highlighting Zola revenue growth, reduced operating expenses, and the termination of a proposed business combination.

Summary

• Net loss attributable to common stockholders significantly improved to $2.3 million for the full year 2025, down from $7.0 million in 2024.
• Fourth-quarter 2025 net loss attributable to common stockholders improved to $1.4 million, compared to $4.1 million in the same period of 2024.
• Zola coconut water brand revenues increased by 17% ($701,000) year-over-year in 2025, driven by increased distribution and sales volume.
• Selling, general, and administrative (SG&A) expenses decreased by approximately 27% ($2.6 million) for the full year 2025 compared to 2024.
• Net cash used in operating activities declined by 49% to $4.7 million in 2025 compared to $9.6 million in 2024.
• The proposed business combination with Roosevelt Resources, signed in December 2024, was terminated at the end of 2025.
• Arcadia Biosciences secured approximately $2.1 million in gross proceeds from the immediate exercise of certain outstanding preferred investment options.
• Total revenues for the full year 2025 decreased by 4% to $4.86 million, primarily due to the absence of GLA oil sales present in 2024.
• Cash and cash equivalents at December 31, 2025, stood at $259,000, a significant decrease from $4.24 million at December 31, 2024.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging report. While cost reductions and Zola's growth are positive, the termination of a key strategic deal, significant cash burn, and explicit need for future funding without assurance of availability indicate substantial operational and financial headwinds.

Positives

• Net loss attributable to common stockholders improved significantly by 67% to $2.3 million for the full year 2025, from $7.0 million in 2024.
• Zola coconut water brand revenues increased by 17% ($701,000) in 2025, outpacing the overall coconut water category.
• Selling, general, and administrative (SG&A) expenses were reduced by 27% ($2.6 million) for the full year 2025.
• Net cash used in operating activities decreased by 49% to $4.7 million in 2025, compared to $9.6 million in 2024.
• Secured $2.1 million in gross proceeds from the exercise of preferred investment options, improving the balance sheet.
• Loss from continuing operations improved by 31% to $2.5 million for the full year 2025.
• A gain of $2.3 million related to Above Food common stock contributed to the improved net loss.
• A $2.0 million gain associated with the reduction of the company's contingent liability in 2025.

Negatives

• The proposed business combination with Roosevelt Resources was terminated at the end of 2025.
• Total revenues decreased by 4% ($187,000) for the full year 2025 to $4.86 million, primarily due to the absence of GLA oil sales.
• Cash and cash equivalents significantly decreased to $259,000 as of December 31, 2025, from $4.24 million as of December 31, 2024.
• A credit loss of $4.745 million was recognized in 2025.
• Net decrease in cash and cash equivalents was larger in 2025 at $3.98 million compared to $2.28 million in 2024.
• Total assets decreased from $13.52 million in 2024 to $6.55 million in 2025.

Risks

• Forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially.
• The company will require additional funding in the near future to continue its operations and planned activities.
• There are no assurances that required funding will be available at all, or will be available in sufficient amounts or on reasonable terms.
• Any sale of additional equity securities could result in dilution to company stockholders.
• Reported results should not be considered as an indication of future performance.

Future Outlook

The company intends to use the proceeds from preferred investment options and other assets to continue growing its Zola coconut water brand while evaluating strategic alternatives. However, the company explicitly states it will require additional funding in the near future to continue operations and planned activities, with no assurances that such funding will be available on reasonable terms or in sufficient amounts.

Management Comments

• "At the end of 2025, we received a termination notice from Roosevelt Resources related to the Securities Exchange Agreement concerning a proposed business combination, signed in December 2024."
• "After receiving this news, we took steps to improve our balance sheet by entering into definitive agreements for the immediate exercise of certain outstanding preferred investment options, resulting in gross proceeds of approximately $2.1 million to Arcadia."
• "We intend to use these proceeds, along with our other assets, to continue growing our Zola coconut water brand while we evaluate strategic alternatives."
• "In 2025, Zola sales growth continued to outpace the coconut water category."
• "At the same time, we reduced our SG&A expenses by approximately 27%, and our net cash used in operating activities declined by 49% in 2025 compared to 2024."

Industry Context

StockSavvy.ai notes that Arcadia Biosciences' focus on its Zola coconut water brand positions it within the growing functional beverage and wellness market. The termination of the Roosevelt Resources business combination suggests a shift in strategic direction, potentially towards a more focused approach on its core consumer brand, which has shown positive growth. The broader industry sees increasing consumer demand for natural, healthy, and plant-based products, which Zola aligns with. However, the competitive landscape for coconut water and wellness products is intense, with established players and new entrants constantly vying for market share.

Comparison to Industry Standards

• The filing does not provide specific comparable company data or industry benchmarks to assess Arcadia's performance against global standards.
• StockSavvy.ai notes that while Zola's 17% revenue growth is positive, it is difficult to benchmark without specific market share data or growth rates of direct competitors like Vita Coco or Harmless Harvest.
• The significant reduction in SG&A expenses and net cash used in operating activities suggests effective cost management, which is a positive sign in a competitive industry, but the overall revenue decline and low cash balance remain concerns.

Related Party Transactions

• Amounts due to related parties totaled $30,000 as of December 31, 2025.

Stakeholder Impact

• Shareholders: Potential for significant dilution if additional equity financing is pursued. The termination of the business combination removes a potential growth avenue. The improved net loss and cost control are positive, but the low cash balance and need for funding are major concerns.
• Employees: No direct impact mentioned, but strategic evaluations and financial pressures could lead to future operational adjustments.
• Customers (Zola): Continued focus on growing the Zola brand suggests ongoing product availability and potential expansion.
• Creditors: The need for additional funding and low cash balance could raise concerns about the company's ability to meet future obligations.

Next Steps

• Continue growing the Zola coconut water brand.
• Evaluate strategic alternatives for the company.
• Seek additional funding through equity or debt financings, asset transactions, or other transactions.

Key Dates

Recommendation

Despite improvements in net loss and Zola's revenue growth, the termination of a significant business combination, critically low cash reserves ($259,000), and the explicit statement that the company "will require additional funding in the near future to continue its operations and planned activities" with "no assurances that required funding will be available at all or will be available in sufficient amounts or on reasonable terms" point to severe liquidity issues and high operational risk. The potential for significant shareholder dilution from future capital raises further exacerbates the negative outlook.

Keywords

Arcadia Biosciences, RKDA, Financial Results, Fourth Quarter 2025, Full Year 2025, Zola Coconut Water, Operating Expenses, Net Loss, Business Combination Termination, Preferred Investment Options, Cash Flow, Wellness Products, SEC Filing, Biotechnology, Consumer Goods